Non-Hodgkin Lymphoma
Cancer burden increasing among younger women, report shows
Cancer incidence has continued to rise in the U.S. since the 1990s — particularly among women and younger adults, according to an American Cancer Society report.
VIDEO: CAR T-cell therapy made in 1 day had good safety, efficacy in phase 1 trial
SAN DIEGO — A new chimeric antigen receptor T-cell therapy option made in less than a day may be a new option for patients with relapsed/refractory non-Hodgkin lymphoma, according to research presented at ASH Annual Meeting and Exposition.
VIDEO: Treatment regimen appears safe, effective in aggressive non-Hodgkin lymphoma
SAN DIEGO — A treatment regimen of loncastuximab tesirine combined with venetoclax may be safe and effective in a subset of patients with non-Hodgkin lymphoma, according to early research presented at ASH Annual Meeting and Exposition.
Axi-cel exhibits durable benefit in advanced indolent non-Hodgkin lymphoma
SAN DIEGO — Treatment with axicabtagene ciloleucel conferred durable benefit to patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.
VIDEO: Dose expansion study performed on novel BCL-2 inhibitor for acute myeloid leukemia
In this video, Noah Merin, MD, PhD, discusses the results of a Chinese study into the use of venetoclax in the treatment of acute myeloid leukemia and non-Hodgkin lymphoma, presented at ESMO Congress.
Despite benefits, many patients with leukemia, lymphoma do not undergo IgG tests
Many patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma do not undergo immunoglobulin G testing despite its potential to reduce likelihood of severe infections.
Armored cells may form ‘an effective strategy’ in lymphoma after CAR-T fails
CHICAGO — Treatment of with an investigational chimeric antigen receptor T-cell therapy showed an acceptable safety profile and produced durable remissions among certain patients with non-Hodgin lymphoma.
Enalapril does not prevent chemotherapy-related heart damage in breast cancer, lymphoma
ATLANTA — Enalapril plus standard care was not superior to standard care alone for preventing cardiotoxicity in patients receiving treatment for breast cancer or lymphoma, according to new data from the PROACT trial.
Drug use during pregnancy linked to certain pediatric cancers
Gestational substance abuse appeared linked to certain cancers among children, according to study results published in Cancer Epidemiology, Biomarkers and Prevention.
FDA requires boxed safety warning for all CAR T-cell therapies
The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.